What is salt-losing enteropathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Salt-Losing Enteropathy?

Salt-losing enteropathy is a pathological condition where the intestine loses more sodium and water into the lumen than it absorbs, resulting in net secretion that leads to dehydration, electrolyte depletion, and secondary hyperaldosteronism if left untreated. 1

Pathophysiology and Mechanisms

Salt-losing enteropathy occurs when the intestinal epithelium becomes abnormally permeable or damaged, allowing sodium-rich fluid to escape into the intestinal lumen at rates exceeding absorptive capacity. 1

Primary Mechanisms

  • Shortened bowel length: When less than 100 cm of jejunum remains after surgical resection, most patients become "net secretors," losing more fluid from their stoma than they consume orally, with stomal fluid containing approximately 90-100 mmol/L sodium (range 80-140 mmol/L). 1

  • Epithelial barrier dysfunction: The leaky intestinal epithelium allows both hypotonic fluids (water, tea, coffee) and hypertonic fluids (fruit juices, sodas) to stimulate fluid secretion or increase sodium and fluid influx into the jejunal lumen, paradoxically worsening stomal losses. 1

  • Inflammatory mucosal damage: Active inflammatory bowel disease, particularly ulcerative colitis, causes impaired colonic capacity to absorb chloride and sodium while retaining the ability to secrete potassium, creating a true salt-losing diarrhea. 2

Secondary Metabolic Consequences

The sodium and water depletion triggers secondary hyperaldosteronism, which compounds the problem by increasing urinary losses of magnesium and potassium. 1 This creates a vicious cycle where magnesium depletion is further worsened by unabsorbed fatty acids binding intraluminal magnesium. 1

Clinical Presentation

Patients with salt-losing enteropathy typically present with:

  • High-output stomas exceeding 2 liters per 24 hours, placing them at particular risk for significant dehydration and electrolyte disturbances. 1

  • Dehydration signs including reduced urine output (less than 800 mL/day), concentrated urine with sodium concentration below 20 mmol/L, and clinical volume depletion. 3

  • Metabolic alkalosis from excessive chloride loss in addition to sodium and water loss, commonly found in active proctocolitis. 2

  • Refractory hypokalemia and hypocalcemia that will not correct until magnesium deficiency is addressed first. 3

Distinction from Protein-Losing Enteropathy

While both conditions involve intestinal losses, salt-losing enteropathy specifically refers to excessive sodium and water loss, whereas protein-losing enteropathy involves loss of serum proteins (particularly albumin) into the gastrointestinal tract. 4, 5 These are distinct pathophysiological processes that may coexist but require different diagnostic and therapeutic approaches. 6

High-Risk Populations

Patients at greatest risk include:

  • Short bowel syndrome patients with reduced jejunal length ending in a stoma, particularly those with less than 100 cm of remaining jejunum. 1

  • Active inflammatory bowel disease patients, especially those with extensive colonic involvement. 2

  • Post-surgical patients in the immediate postoperative hypersecretory phase following intestinal resection. 3

Critical Diagnostic Indicators

The diagnosis is primarily clinical, based on:

  • Stomal output volume consistently exceeding 1200 mL/day despite oral intake restriction. 3

  • Urine sodium concentration below 20 mmol/L with reduced urine volume, indicating inadequate sodium repletion. 3

  • Elevated renin and aldosterone levels confirming secondary hyperaldosteronism from chronic volume depletion. 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Salt-losing diarrhoea in idiopathic proctocolitis.

Scandinavian journal of gastroenterology, 1978

Guideline

Management of Salt-Losing Enteropathy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Protein-losing enteropathy.

Current opinion in gastroenterology, 2020

Research

Clinical practice. Protein-losing enteropathy in children.

European journal of pediatrics, 2010

Related Questions

What is the primary management for a patient with salt-losing enteropathy?
How is protein losing enteropathy (PLE) evaluated and managed?
What is the treatment approach for protein losing enteropathy?
What is protein-losing enteropathy (protein enteropathy)?
What are the treatment options for hypoproteinemia (low protein levels)?
Why is parecoxib (COX-2 inhibitor) not approved by the regulatory agency (Food and Drug Administration (FDA))?
What could be causing pain to the left side of the cesarean section (C-section) scar in a 3-week postpartum female with no signs of infection, such as fever or discharge?
What does it mean if a patient has a normal High-Density Lipoprotein (HDL) level, normal Low-Density Lipoprotein (LDL) and triglyceride levels, but an elevated total cholesterol level, and how should it be managed?
When should fibrate (fibrate) therapy be initiated in a patient with dyslipidemia, elevated triglyceride levels, and low high-density lipoprotein (HDL) cholesterol, who has not responded to lifestyle modifications or other treatments?
What is the best course of action for a patient in their 50s with a history of acute pancreatitis secondary to a large intraductal papillary mucinous neoplasm (IPMN), presenting with worsening epigastric pain, fevers, nausea, cholestatic injury, elevated lipase, and hyponatremia?
What is the typical treatment protocol and need for long-term maintenance sessions for Transcranial Magnetic Stimulation (TMS) therapy in an adult patient with treatment-resistant depression?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.